The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...

All the companies have skin in the game for clotting/bleeding disorders. The BMS-Pfizer Alliance market Factor Xa blood ...

As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.

Activist investor Starboard Value claims the pharma giant’s former CEO and CFO were “threatened” into backing current ...

The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...

Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...

当地时间10月11日，美国FDA批准辉瑞（Pfizer）药品Hympavzi（marstacimab）用于常规预防或减少12岁及以上血友病A和血友病B成人和儿童患者的出血，这些患者体内不含凝血因子VIII与IX抑制剂（中和抗体）。